21/09/2022, 08:30 Emerging therapies in advanced AL amyloidosis | medthority.com https://www.medthority.com/international-symposium-on-amyloidosis-2022-highlights/emerging-therapies-in-advanced-al-amyloidosis/ 1/4 Hello User Account Log out 0 Search Menu Home / International Symposium on Amyloidosis 2022 Highli... / Emerging therapies in advanced AL amyloidosis Emerging therapies in advanced AL amyloidosis Read time: 0 mins Last updated: 13th Sep 2022 Published: 13th Sep 2022 Author: By Simon van Rysewyk, PhD Bookmark Share The second highlight article from the 18 International Symposium on Amyloidosis (ISA) 2022 is an overview of the Satellite Symposium, ‘Addressing the Unmet Need in Advanced AL Amyloidosis: Key insights from a panel of experts,’ presented by Morie Gertz (Mayo Clinic, USA), on Tuesday 6, September 2022, in Heidelberg, Germany. th Investigational anti-amyloid agents CAEL-101 clinical trials Birtamimab clinical trials Conclusions Investigational anti-amyloid monoclonal antibodies Professor Morie Gertz begins with a cautionary note against focusing too much attention on anti-amyloid treatments that target production of free light-chain amyloid proteins. He urges the development of more anti-amyloid treatments that reduce or eliminate pre-existing amyloid deposits in bodily tissues. Two investigational anti-amyloid monoclonal antibodies for amyloid light-chain (AL) amyloidosis in phase 3 trials are: CAEL-101 Birtamimab CAEL-101 is a chimeric mAb that targets AL amyloid deposits . Birtamimab is a fully humanised monoclonal antibody (mAb) that targets soluble AL aggregates, and insoluble AL amyloid deposits . Soluble AL aggregates could be part of the cellular toxicity of free light-chains. 4,5 6,7 Recommended reading for you